"Oncolytics Biotech Inc. announced today that it has successfully completed its lyophilization (freeze-drying) formulation development program for REOLYSIN®". 

"REOLYSIN®, the company's proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway.  Reovirus, an acronym for Respiratory Enteric Orphan virus, is generally believed to inhabit the respiratory and bowel systems in humans.  REOLYSIN® may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders".

"This is the final step in the development of our manufacturing process for REOLYSIN®," said Dr. Matt Coffey, Chief Operating Officer for Oncolytics.  "Lyophilized product is the standard end use formulation for commercial use of the product". 

"The lyophilization program was completed in cooperation with the National Research Council Biotechnology Research Institute (NRC-BRI) of Montreal, Canada and Lyophilization Technology, Inc. of Ivyland, Pennsylvania."